Disease · MONDO_0006570

lichen disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lichen disease. Diseases, record MONDO_0006570. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006570

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lichen disease; Open Targets
Open Targets ID: MONDO_0006570; Open Targets
Other names: lichen, lichen sclerosus; Open Targets
Disease Ontology: DOID:8574; Disease Ontology
Highest stage of its drugs: Phase 3, for 4 of its 25 drugs, from ClinicalTrials.gov; Open Targets

Drugs25

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CLOBETASOL PROPIONATE	CHEMBL1159650	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CARBON DIOXIDE	CHEMBL1231871	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CLOBETASOL	CHEMBL1201362	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DELGOCITINIB	CHEMBL4297507	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PIMECROLIMUS	CHEMBL1200686	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PROGESTERONE	CHEMBL103	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TACROLIMUS	CHEMBL3989887	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 1	ClinicalTrials.gov	3	3	1	Drugs and targets

1 to 10 of 25

See all 25 drugs

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	13	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
JAK1	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Phase 3	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Phase 3	https://conductscience.org/library/genes/3718	Drugs and targets
TYK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor	Phase 3	https://conductscience.org/library/genes/7297	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
PGR	Progesterone receptor	1	Progesterone receptor agonist	Phase 2	https://conductscience.org/library/genes/5241	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/11280	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05593445	A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus	Phase 2	61	2024-09-24	Lichen Sclerosus	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT02573883	Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus	Phase 3	52	2021-10-12	Vulvar Lichen Sclerosus	CARBON DIOXIDE, CLOBETASOL PROPIONATE	Its record names the disease	ClinicalTrials.gov
NCT07335588	A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus	Phase 3	652		Lichen Sclerosus	DELGOCITINIB	Its record names the disease	ClinicalTrials.gov
NCT05010421	Laser vs Clobetasol for Lichen Sclerosus	Phase 3	246		Lichen Sclerosus	CARBON DIOXIDE, CLOBETASOL	Its record names the disease	ClinicalTrials.gov
NCT05228483	Carbon Dioxide（CO2）Fractional Laser Plus Photodynamic Therapy in Female Patients With Vulvar Lichen Sclerosus	Not applicable	134		Vulva Lichen Sclerosus	MOMETASONE FUROATE	Its record names the disease	ClinicalTrials.gov
NCT06135402	Comparison of Laser Treatment With Clobetasol Therapy in Patients With Lichen Sclerosus	Not applicable	120		Lichen Sclerosus	CLOBETASOL PROPIONATE	Its record names the disease	ClinicalTrials.gov
NCT03200808	Methylene Blue Injection for Nonneoplastic Epithelial Disorders of Vulva	Phase 1	118		Nonneoplastic Epithelial Disorders of Vulva	DEXAMETHASONE, METHYLENE BLUE, ROPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT00757874	Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus	Phase 2	56		Vulvar Lichen Sclerosus	CLOBETASOL PROPIONATE, TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00393263	Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus	Phase 2	38		Lichen Sclerosus	CLOBETASOL, PIMECROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01126255	Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus	Phase 2	37		Vulvar Lichen Sclerosus	CLOBETASOL PROPIONATE, PROGESTERONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: deaths from any cause	0 of 58	0 of 30	88	NCT05593445	Trial comparisons
Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: serious adverse events	0 of 58	1 of 30	88	NCT05593445	Trial comparisons
DBVC Period: Ruxolitinib Cream 1.5% BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any ≥Grade 3 TEAE During the Double-blind, Vehicle-controlled Period	1 of 31	0 of 30	61	NCT05593445	Trial comparisons
DBVC Period: Ruxolitinib Cream 1.5% BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any Clinically Meaningful Changes Over Time in Clinical Laboratory Test Results During the Double-blind, Vehicle-controlled Period	0 of 31	0 of 30	61	NCT05593445	Trial comparisons
DBVC Period: Ruxolitinib Cream 1.5% BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any Clinically Meaningful Changes Over Time in Vital Sign Values During the Double-blind, Vehicle-controlled Period	0 of 31	0 of 30	61	NCT05593445	Trial comparisons
DBVC Period: Ruxolitinib Cream 1.5% BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) During the Double-blind, Vehicle-controlled Period	14 of 31	12 of 30	61	NCT05593445	Trial comparisons
DBVC Period: Ruxolitinib Cream 1.5% BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any Clinically Meaningful Changes Over Time in Clinical Laboratory Test Results During the Open-label Extension Period	0 of 29	0 of 27	56	NCT05593445	Trial comparisons
DBVC Period: Ruxolitinib Cream 1.5% BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any Clinically Meaningful Changes Over Time in Vital Sign Values During the Open-label Extension Period	0 of 29	0 of 27	56	NCT05593445	Trial comparisons
DBVC Period: Ruxolitinib Cream 1.5% BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any TEAE During the Open-label Extension Period	13 of 29	11 of 27	56	NCT05593445	Trial comparisons
DBVC Period: Ruxolitinib Cream 1.5% BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any ≥Grade 3 TEAE During the Open-label Extension Period	1 of 29	0 of 27	56	NCT05593445	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35290878	RESULT	1	PubMed
21353334	RESULT	1	PubMed
15568399	RESULT	1	PubMed
42208069	DERIVED	1	PubMed
33957642	DERIVED	1	PubMed
31628667	DERIVED	1	PubMed
28793884	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006570

GET https://conductscience.org/api/diseases/v1/MONDO_0006570/drugs?page=2

API reference For AI assistants